BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12784654)

  • 1. [Pathophysiology and treatment of acute myeloid leukemia].
    Naoe J
    Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
    Spiekermann K; Hiddemann W; Schnittger S
    Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular targets and the treatment of myeloid leukemia.
    Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
    Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
    Dvorak P; Hruba M; Subrt I
    Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment strategies for chronic myeloid leukemia].
    Jinnai I
    Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 8. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLT3 inhibition as tailored therapy for acute myeloid leukemia.
    Martinelli G; Piccaluga PP; Lo Coco F
    Haematologica; 2003 Jan; 88(1):4-8. PubMed ID: 12551818
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosine kinases as targets for cancer therapy.
    Krause DS; Van Etten RA
    N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 14. No correlation between trisomy 13 and FLT3 duplication in acute myeloid leukemia.
    Powell H; Curtis A; Bown N; Taylor P
    Cancer Genet Cytogenet; 2005 Jan; 156(1):92-3. PubMed ID: 15588866
    [No Abstract]   [Full Text] [Related]  

  • 15. [Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies].
    Turhan AG
    Bull Cancer; 2005 Jan; 92(1):75-82. PubMed ID: 15689327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 Inhibitors in the Treatment of AML.
    Gilliland DG
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
    [No Abstract]   [Full Text] [Related]  

  • 17. FLT-3: a new focus in the understanding of acute leukemia.
    Markovic A; MacKenzie KL; Lock RB
    Int J Biochem Cell Biol; 2005 Jun; 37(6):1168-72. PubMed ID: 15778081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
    Schafhausen P; Dierlamm J; Bokemeyer C; Bruemmendorf TH; Bacher U; Zander AR; Schnittger S; Hochhaus A
    Cancer Genet Cytogenet; 2009 Feb; 189(1):63-7. PubMed ID: 19167615
    [No Abstract]   [Full Text] [Related]  

  • 19. [Detection of FLT3 gene and FLT3/ITD gene mutation in chronic myeloid leukemia and its significance].
    Xu B; Tian H; Zhou SY
    Ai Zheng; 2004 Oct; 23(10):1218-21. PubMed ID: 15473940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.